Merck teams with Affimed on immuno-oncology combo

Germany's Affimed has inked a deal that makes it the latest in a long string of biotechs to partner up with Merck ($MRK) on a combination study using the PD-1 blockbuster Keytruda. Affimed is underwriting a Phase Ib study that combined its drug AFM13 with Keytruda against Hodgkin lymphoma. AFM13 is a bispecific antibody that is designed to engage NK (natural killer) cells. And Affimed has rights to spring forward into Phase III, if the data look right. Release

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.